Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Cytokine1 who wrote (5697)	10/1/1998 10:20:00 AM
From: Rocketman	Read Replies (2) \| Respond to of 9719

Schering-Plough and Incyte Pharmaceuticals Enter Into Genomic Data Collaboration Thursday October 1, 8:34 am Eastern Time Company Press Release SOURCE: Schering-Plough Corporation MADISON, N.J. and PALO ALTO, Calif., Oct. 1 /PRNewswire/ -- Schering-Plough Corporation (NYSE: SGP - news) and Incyte Pharmaceuticals Inc. (Nasdaq: INCY - news) today announced that they have entered into a broad genomic data collaboration which provides Schering-Plough with access to Incyte's microarray technology and databases. Incyte will provide Schering-Plough with data from custom and prefabricated DNA microarrays in exchange for technology access and per-array fees. The multi-year collaboration also provides Schering-Plough with access to Incyte's LifeSeq(R) gene sequence and expression database and the LifeSeq FL(R) database of full-length genes. Financial terms of the agreement were not disclosed. The agreement provides Schering-Plough researchers with data from microarrays based on high-quality proprietary gene sequences from the LifeSeq and LifeSeq FL databases. The microarray technology will assist Schering- Plough scientists in discovering new therapeutic targets in various research programs. The LifeSeq and LifeSeq FL databases will be accessed at several Schering-Plough research sites worldwide, including Schering-Plough Research Institute in New Jersey and DNAX Research Institute and Canji, Inc., in California. ''Schering-Plough is experienced in the use of genomic tools for research, and we are pleased to be working with them in this collaboration,'' said Roy A. Whitfield, chief executive officer of Incyte. ''The LifeSeq databases and microarrays provide Schering-Plough with powerful tools for today's medical research.'' The agreement marks Incyte's third high-volume microarray technology access agreement since May. Incyte's integrated platform allows researchers to seamlessly compare results from microarray experiments with Incyte databases, enabling them to study disease pathways and monitor gene expression. Incyte Pharmaceuticals Inc. is a leading provider of an integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. The Incyte General division develops and markets gene discovery and expression products -- including databases, genomic data management software, microarray-based gene expression services, and related reagents -- enabling the pharmaceutical industry to identify new targets and pathways for drug discovery and development. The Incyte Genetics division will provide databases, bioinformatics, and services relating to sequencing and mapping the human genome and identifying gene sequence variation, enabling the pharmaceutical industry to utilize pharmacogenetics as an integral part of pharmaceutical discovery and development. For more information, visit Incyte's web site at www.incyte.com. Schering-Plough is a research-based company engaged in the discovery, development, manufacturing and marketing of pharmaceutical and health care products worldwide. INCYTE PHARMACEUTICALS INC. DISCLOSURE STATEMENT: Except for the historical information contained herein, the matters set forth in this press release, including statements as to the ability of Incyte's microarrays to assist in the development of new therapeutic targets, are forward-looking statements within the meaning of the ''safe harbor'' provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the utilization of microarrays and databases in Schering-Plough's research programs, the impact of technological advances in competition, and other risks detailed from time to time in Incyte's SEC reports, including its Report on Form 10-Q for the quarter ended June 30, 1998. These forward-looking statements speak only as of the date hereof. Incyte disclaims any intent or obligation to update these forward-looking statements. >>>>>>>>> The deals are starting to flow again! Rman

To: Cytokine1 who wrote (5697)	10/1/1998 12:23:00 PM
From: Rocketman	Respond to of 9719

COVER ICOS SHORT AT $18 1/16 Rman

To: Cytokine1 who wrote (5697)	10/1/1998 7:42:00 PM
From: Cytokine1	Read Replies (1) \| Respond to of 9719

VD's MODEL PORTFOLIO 10/1/98 Change -$7832 DOWN -4.94% Started 4/9/97, $100K . INDEX ^IXB DOWN -3.72% YTD EQUITY CHANGE -17.0% # CURRENT DAILY CURRENT COST TOTAL %GAIN/ % OF SYMBOL SHRS PRICE CHANGE %CHG VALUE SHR COST LOSS TOTAL ======= ======= ======= ======= ======= ======= ======= ======= ======= ======= CLTR 1000 23.25 -1.63 -6.53% 23250 10.88 10875 113.8% 15.4% SEPR 272 63.63 -2.13 -3.23% 17306 37.55 10214 69.4% 11.5% GENZ 830 34.13 -2.00 -5.54% 28324 25.17 20893 35.6% 18.8% AGPH 300 33.50 -0.94 -2.72% 10050 26.00 7800 28.8% 6.7% MOGN 2000 6.88 -0.31 -4.35% 13750 7.00 14000 -1.8% 9.1% DURA 200 9.81 -1.13 -10.29% 1963 24.63 4925 -60.2% 1.3% INCY 1000 20.94 -0.31 -1.47% 20938 29.41 29409 -28.8% 13.9% MLNM 300 15.63 -1.75 -10.07% 4688 18.63 5588 -16.1% 3.1% GZTC 2000 3.88 -0.13 -3.13% 7750 7.737 15475 -49.9% 5.1% ABSC 2000 5.13 -0.88 -14.58% 10250 8.735 17470 -41.3% 6.8% LGNDW 3000 4.13 0.00 0.00% 12375 8.75 26250 -52.9% 8.2% STOCK ______ ______ ______ ______ 150642 162898 -7.5% 100.0% SHORT SALE CREDIT ______ ______ MARGIN MTCE. EQUITY 47.8% MIN 30% (74577) BUYING POWER $ ______ -6262 EQUITY (NAV) ______ ______ ______ 76065 100000 -23.9% ^IXB INDEX 306.65 -11.84 -3.72% 302.42 1.4% NOTES: OPEN orders subject to available buying power--- Open limit sell order, 260 shrs GENZ @ $40 10/1/98 -168.75 ICOS covered short, 300 shrs @ 18.0625 8/21/98 5250.00 ICOS sold short 300 @ $17.50 8/21/98 12436.875 AVIR sold 737 @ $28.94, loss 40.4%